



**NEW**  
**vet**  **medin**<sup>®</sup>  
ORAL SOLUTION

---

HOW DO YOU  
**DELAY**  
HEART DISEASE  
FOR EVEN THE  
**TRICKIEST**  
**PATIENTS?**

---

One drop at a time with New  
VETMEDIN<sup>®</sup> Oral Solution

# HEART DISEASE: COMMON, YET CAN BE TRICKY TO TREAT

## PREVALENT IN DOGS

- Approximately **10% of all dogs** have heart disease<sup>1</sup>
- **75–80%** is classified as myxomatous mitral valve disease (MMVD)<sup>1,2</sup>
- **MMVD** primarily affects **small breeds**<sup>3</sup>



## TREATING HEART DISEASE CAN BE CHALLENGING



### Small and toy breeds

- Achieving **precise dosing** can be **difficult** and may lead to under or overdosing of treatment
- Toy breeds can be **picky eaters** and **may not accept tablets**



### Patients with other conditions

- Those with **dental issues** may struggle to take chewable medication
- Side effects can occur if they **suffer from sensitivities** such as allergies



### Dogs of any size

- **May be reluctant** to accept or **fear of taking tablets**

**Small and toy breeds  
are notoriously  
difficult to pill.**

Sonya Gordon, DVM, DACVIM Cardiology, Professor  
and Eugene Ch'en Chair in Veterinary Cardiology at  
Texas A&M University

DIFFICULTIES IN ADMINISTERING MEDICATION CAN LEAD TO PET OWNER  
FRUSTRATION AND A LACK OF COMPLIANCE

# INTRODUCING VETMEDIN® ORAL SOLUTION

**NEW**  
**vetmedin®**  
ORAL SOLUTION



## DESIGNED TO TREAT EVEN THE TRICKIEST PATIENTS

### VETMEDIN® Oral Solution:

- Is the **only liquid oral formulation** of pimobendan<sup>4</sup>
- Is licensed for the treatment of **congestive heart failure (CHF)** and **preclinical heart disease**<sup>4,5</sup>



### Precise dosing for effective treatment

- Syringe and body weight increments ensure **accurate dosing**, especially in **small patients**
- Promotes **less treatment waste**
- **Bioequivalence with VETMEDIN® tablets** and twice-daily dosing<sup>4</sup>



### Simple administration supports long-term compliance

- **Ready-to-use** and **easy-to-give** oral treatment<sup>4</sup>
- Sweet taste that promotes **high acceptability\***
- **Ideal for small patients** used to liquid treatments or patients **not willing to take chews**



### Well tolerated by dogs with sensitivities

- Optimal treatment for those with a sensitive digestive system, as proven to be **gentle on the stomach\***
- Suitable for patients **allergic to animal protein**<sup>4</sup>



### Convenient storage for easier use in everyday life

- **No specific storage requirements** and no need for refrigeration<sup>4</sup>
- **8 weeks** in-use shelf life



SCAN HERE TO SEE HOW TO EASILY ADMINISTER  
VETMEDIN® ORAL SOLUTION

# VETMEDIN® ORAL SOLUTION

## COMPLETES THE VETMEDIN® FAMILY FOR MAXIMUM FLEXIBILITY



Wide variety of formulations:

- Chewable tablets and capsules of varying strengths
- Solution for injection
- And now, oral solution<sup>4</sup>

Allows you to prescribe the most suitable option for your patients

### For over 25 years, VETMEDIN® has been leading the way in canine cardiology, with continuous innovations and landmark research studies

- In dogs with preclinical (Stage B2) MMVD, treatment with **VETMEDIN®** was shown to prolong the preclinical period (Stage B2) **by a mean of 15 months\*\***, giving more quality time in the **asymptomatic stage<sup>6</sup>**
- Licensed for the **treatment of preclinical heart disease** in both **MMVD** and dilated cardiomyopathy (**DCM<sup>5</sup>**)
- The **only treatment strongly recommended by the ACVIM** for dogs with preclinical heart disease (Stage B2)<sup>7</sup>

**vetmedin®**

**DEDICATED TO IMPROVING PATIENT QUALITY OF LIFE AND PROVIDING MORE LIFE TO LOVE**

\*Global study showing the ability to administer VETMEDIN® Oral Suspension onto a small amount of food. Boehringer Ingelheim, Data on file.

\*\*The composite primary endpoint was defined as the onset of left-sided CHF, cardiac-related death or euthanasia; dogs in the VETMEDIN® group were significantly less likely to reach this endpoint. Median time to composite primary endpoint was 1228 days in the VETMEDIN® group and 766 days in the placebo group (P=0.0038).

Scan the QR code or view the package inserts of our products at [www.boehringer-ingelheim.nl/hond](http://www.boehringer-ingelheim.nl/hond)

**References:** **1.** Rush JE. Chronic valvular heart disease in dogs. Proceedings from the 26th Annual Waltham Diets/OSU Symposium for the Treatment of Small Animal Cardiology; October 19–20, 2002. **2.** Atkins C, Bonagura J, Ettinger S, et al. Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. *J Vet Intern Med.* 2009;23:1142–1150. **3.** Guglielmini C. Cardiovascular diseases in the aging dog: diagnostic and therapeutic problems. *Vet Res Commun.* 2003;27 Suppl 1:555–560. **4.** VETMEDIN® Summary of Product Characteristics. Available at: [www.boehringer-ingelheim.nl/hond](http://www.boehringer-ingelheim.nl/hond). Accessed: 09/2025. **5.** VETMEDIN Oral Solution SPC from the UK – accessible at: [https://www.vmd.defra.gov.uk/productinformationdatabase/files/SPC\\_Documents/SPC\\_2961089.PDF](https://www.vmd.defra.gov.uk/productinformationdatabase/files/SPC_Documents/SPC_2961089.PDF). **6.** Boswood A, Häggström J, Gordon SG, et al. Effect of pimobendan in dogs with preclinical myxomatous mitral valve disease and cardiomegaly: the EPIC Study—a randomized clinical trial. *J Vet Intern Med.* 2016;30:1765–1779. **7.** Summerfield NJ, Boswood A, O’Grady MR, et al. Efficacy of pimobendan in the prevention of congestive heart failure or sudden death in Doberman Pinschers with preclinical dilated cardiomyopathy (the PROTECT Study). *J Vet Intern Med.* 2012;26:1337–1349.

